A detailed history of Black Rock Inc. transactions in Relay Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 9,796,210 shares of RLAY stock, worth $63.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
9,796,210
Previous 9,573,423 2.33%
Holding current value
$63.9 Million
Previous $105 Million 22.86%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$7.5 - $12.07 $1.67 Million - $2.69 Million
222,787 Added 2.33%
9,796,210 $81.3 Million
Q4 2023

Feb 13, 2024

BUY
$6.01 - $11.48 $7.47 Million - $14.3 Million
1,243,656 Added 14.93%
9,573,423 $105 Million
Q3 2023

Nov 13, 2023

SELL
$8.24 - $12.97 $312,798 - $492,354
-37,961 Reduced 0.45%
8,329,767 $70.1 Million
Q2 2023

Aug 11, 2023

BUY
$9.99 - $18.27 $4.32 Million - $7.89 Million
432,038 Added 5.44%
8,367,728 $105 Million
Q1 2023

May 12, 2023

SELL
$15.0 - $22.76 $934,425 - $1.42 Million
-62,295 Reduced 0.78%
7,935,690 $131 Million
Q4 2022

Feb 13, 2023

BUY
$14.16 - $24.02 $17.6 Million - $29.8 Million
1,240,348 Added 18.35%
7,997,985 $119 Million
Q3 2022

Nov 14, 2022

BUY
$18.07 - $31.37 $3.26 Million - $5.66 Million
180,459 Added 2.74%
6,757,637 $151 Million
Q2 2022

Aug 12, 2022

BUY
$13.31 - $34.88 $8.03 Million - $21 Million
602,995 Added 10.09%
6,577,178 $110 Million
Q1 2022

May 12, 2022

SELL
$20.26 - $32.36 $393,651 - $628,754
-19,430 Reduced 0.32%
5,974,183 $179 Million
Q4 2021

Feb 10, 2022

BUY
$26.0 - $37.03 $16.7 Million - $23.7 Million
641,001 Added 11.98%
5,993,613 $184 Million
Q3 2021

Nov 09, 2021

BUY
$29.75 - $37.99 $24.2 Million - $30.9 Million
812,282 Added 17.89%
5,352,612 $169 Million
Q2 2021

Aug 11, 2021

BUY
$27.5 - $38.19 $125 Million - $173 Million
4,540,330 New
4,540,330 $166 Million

Others Institutions Holding RLAY

About Relay Therapeutics, Inc.


  • Ticker RLAY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 120,219,000
  • Market Cap $784M
  • Description
  • Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...
More about RLAY
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.